Recently, some therapies targeted against BRAF mutations (Vemurafenib, Dabrafenib), KIT mutations (Imatinib) and inhibitor of MEK1 and MEK2 (Trametinib) showed good results in advanced stage melanoma [26–29]. This evidence concerns the gene MAP2K1 and melanoma.